Gland Pharma Limited — Updates, 20-05-2025: Press Release

Gland Pharma has announced a board meeting to approve the financial results for the quarter and half-year. Q4 revenue dipped 7% YoY to ₹1,424.9 Cr, but EBITDA margin rose 100 bps to 24%, driven by strong U.S. volumes and high-margin launches. Base business revenue fell 12% YoY, with EBITDA margin up 100 bps to 38%. The company launched four new injectables, filed 5 ANDAs, and received 7 approvals. Growth continues in biologics CDMO, RTU bags, and GLP-1 capacity. Cenexi’s revenue rose 8% YoY with capacity ramp-ups; positive EBITDA expected by Q3FY26. Final dividend proposed at ₹18/share.